IDH2 and neoplasm: Variability of tumor-cell content, sequence coverage and efficacy of variant calling probably contributed most to the discrepancy with other reports, most of which found the highest mutation rate to be in the TET2 gene, followed by RHOA. Mutations of TET2, IDH2 and DNMT3A usually coexist in AITL patients, unlike the case of myeloid neoplasm, in which TET2 and IDH2 mutations appear to be mutually exclusive.